U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Endometrial Serous Adenocarcinoma

MedGen UID:
1677379
•Concept ID:
C4764206
•
Neoplastic Process

Definition

Endometrial serous adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Endometrial Serous Adenocarcinoma

Professional guidelines

PubMed

Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M, Khemapech N
Asian Pac J Cancer Prev 2013;14(12):7669-74. doi: 10.7314/apjcp.2013.14.12.7669. PMID: 24460351
Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E
Oncology 2007;73(3-4):177-84. Epub 2008 Apr 16 doi: 10.1159/000127384. PMID: 18418010

Recent clinical studies

Etiology

Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH
Int J Gynecol Cancer 2015 Jul;25(6):1015-22. doi: 10.1097/IGC.0000000000000453. PMID: 26098089Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N, Oranratanaphan S, Termrungruanglert W, Lertkhachonsuk R, Vasurattana A
Asian Pac J Cancer Prev 2013;14(3):2131-5. doi: 10.7314/apjcp.2013.14.3.2131. PMID: 23679331
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM
Cancer Immunol Immunother 2011 Jul;60(7):975-84. Epub 2011 Apr 2 doi: 10.1007/s00262-011-1010-x. PMID: 21461842

Diagnosis

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD
Gynecol Oncol 2021 Nov;163(2):334-341. Epub 2021 Aug 25 doi: 10.1016/j.ygyno.2021.08.014. PMID: 34452746Free PMC Article
Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC
Gynecol Oncol 2018 May;149(2):291-296. Epub 2018 Mar 14 doi: 10.1016/j.ygyno.2018.02.022. PMID: 29550183
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH
Int J Gynecol Cancer 2015 Jul;25(6):1015-22. doi: 10.1097/IGC.0000000000000453. PMID: 26098089Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.
El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD
Br J Cancer 2010 Jan 5;102(1):134-43. Epub 2009 Nov 17 doi: 10.1038/sj.bjc.6605448. PMID: 19920829Free PMC Article

Therapy

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD
Gynecol Oncol 2021 Nov;163(2):334-341. Epub 2021 Aug 25 doi: 10.1016/j.ygyno.2021.08.014. PMID: 34452746Free PMC Article
Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC
Gynecol Oncol 2018 May;149(2):291-296. Epub 2018 Mar 14 doi: 10.1016/j.ygyno.2018.02.022. PMID: 29550183
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM
Cancer Immunol Immunother 2011 Jul;60(7):975-84. Epub 2011 Apr 2 doi: 10.1007/s00262-011-1010-x. PMID: 21461842

Prognosis

Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells.
Mise Y, Hamanishi J, Daikoku T, Takamatsu S, Miyamoto T, Taki M, Yamanoi K, Yamaguchi K, Ukita M, Horikawa N, Abiko K, Murakami R, Furutake Y, Hosoe Y, Terakawa J, Kagabu M, Sugai T, Osakabe M, Fujiwara H, Matsumura N, Mandai M, Baba T
Carcinogenesis 2022 Aug 30;43(7):647-658. doi: 10.1093/carcin/bgac032. PMID: 35353883
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD
Gynecol Oncol 2021 Nov;163(2):334-341. Epub 2021 Aug 25 doi: 10.1016/j.ygyno.2021.08.014. PMID: 34452746Free PMC Article
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.
Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH
Int J Gynecol Cancer 2015 Jul;25(6):1015-22. doi: 10.1097/IGC.0000000000000453. PMID: 26098089Free PMC Article
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151

Clinical prediction guides

Immunosuppressive tumor microenvironment in uterine serous carcinoma via CCL7 signal with myeloid-derived suppressor cells.
Mise Y, Hamanishi J, Daikoku T, Takamatsu S, Miyamoto T, Taki M, Yamanoi K, Yamaguchi K, Ukita M, Horikawa N, Abiko K, Murakami R, Furutake Y, Hosoe Y, Terakawa J, Kagabu M, Sugai T, Osakabe M, Fujiwara H, Matsumura N, Mandai M, Baba T
Carcinogenesis 2022 Aug 30;43(7):647-658. doi: 10.1093/carcin/bgac032. PMID: 35353883
Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC
Gynecol Oncol 2018 May;149(2):291-296. Epub 2018 Mar 14 doi: 10.1016/j.ygyno.2018.02.022. PMID: 29550183
Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K, Gounaris I, Basu B, Freeman S, Moyle P, Hosking K, Iddawela M, Jimenez-Linan M, Abraham J, Brenton J, Hatcher H, Earl H, Parkinson C
Int J Gynecol Cancer 2015 Jul;25(6):977-84. doi: 10.1097/IGC.0000000000000448. PMID: 25962114Free PMC Article
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Pitakkarnkul S, Tangjitgamol S, Srijaipracharoen S, Manusirivithaya S, Pataradool K, Prutthiphongsit W, Khunnarong J, Thavaramara T
Asian Pac J Cancer Prev 2013;14(4):2421-7. doi: 10.7314/apjcp.2013.14.4.2421. PMID: 23725151
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma.
Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD
Br J Cancer 2010 Sep 7;103(6):812-9. Epub 2010 Aug 10 doi: 10.1038/sj.bjc.6605760. PMID: 20700124Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...